Analysts Set Epizyme Inc (EPZM) Price Target at $22.67

Shares of Epizyme Inc (NASDAQ:EPZM) have received a consensus recommendation of “Buy” from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $22.67.

A number of analysts have commented on the company. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Oppenheimer set a $26.00 target price on Epizyme and gave the stock a “buy” rating in a report on Tuesday, December 12th. Cann reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Thursday, November 2nd. Finally, Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd.

Several institutional investors and hedge funds have recently modified their holdings of the stock. NEA Management Company LLC grew its holdings in shares of Epizyme by 3.2% in the third quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock worth $123,079,000 after acquiring an additional 200,000 shares during the period. Palo Alto Investors LLC grew its holdings in shares of Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after acquiring an additional 907,245 shares during the period. Vanguard Group Inc. grew its holdings in shares of Epizyme by 6.2% in the second quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after acquiring an additional 200,982 shares during the period. State Street Corp grew its holdings in shares of Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after acquiring an additional 658,727 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Epizyme in the third quarter worth $17,591,000. 85.29% of the stock is owned by institutional investors.

Epizyme (EPZM) traded up $0.05 during trading on Friday, hitting $16.45. The company’s stock had a trading volume of 508,572 shares, compared to its average volume of 541,107. The company has a market cap of $1,140.00, a price-to-earnings ratio of -7.25 and a beta of 2.00. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. research analysts predict that Epizyme will post -2.23 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Epizyme Inc (EPZM) Price Target at $22.67” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://weekherald.com/2018/02/15/analysts-set-epizyme-inc-epzm-price-target-at-22-67.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply